P53

AYEDA AYED is on leave from the Ontario Cancer Institute at the University of Toronto where she worked as a Postdoctoral Fellow and Associate Scientist on structural aspects of p53 using nuclear Magnetic Resonance Spectroscopy. She was the recipient of the Governor General's Award in Leukemia Research and a National Cancer Institute Fellowship. She obtained her PhD in Chemistry at the University of Manitoba in Winnipeg and currently resides in Toronto, Canada.THEODORE HUPP was trained in Chemistry as an undergraduate at Bowling Green State University in Ohio working with Bill Scovell and applied developing interests in life sciences towards a PhD degree at Michigan State University under the mentorship of Jon Kaguni. Interests in enzymology was applied to the cancer field working with Sir David Lane during the time when the p53 field was discovering key p53-inducible genes like p21, transgenic technologies showed  the key role of p53 as a tumor suppressor, and the p53 protein was found to amenable to activation by post-translational modifications such as phosphorylation, ubiquitination, peptide ligands, or small molecules. The Hupp lab is now based at the University of Edinburgh (UK) funded by the Cancer Research UK charity, where enthusiastic students and colleagues continue to study fundamental enzymological aspects of p53 control by ubiquitination, acetylation, and phosphorylation with the hope of developing novel therapeutics for activating the p53 pathway in human cancers.